Flow Cytometry for the Diagnosis of Primary Immunodeficiency Diseases: A Single Center Experience
- Authors
- Kwon, Won Kyung; Choi, Sooln; Kim, Hee-jin; Huh, Hee Jae; Kang, Ji-Man; Kim, Yae-Jean; Yoo, Keon Hee; Ahn, Kangmo; Cho, Hye Kyung; Peck, Kyong Ran; Jang, Ja-Hyun; Ki, Chang-Seok; Kang, Eun-Suk
- Issue Date
- Mar-2020
- Publisher
- KOREAN ACAD ASTHMA ALLERGY & CLINICAL IMMUNOLOGY
- Keywords
- Primary immunodeficiency; diagnosis; phenotype; flow cytometry; genetic testing
- Citation
- ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, v.12, no.2, pp.292 - 305
- Journal Title
- ALLERGY ASTHMA & IMMUNOLOGY RESEARCH
- Volume
- 12
- Number
- 2
- Start Page
- 292
- End Page
- 305
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/26084
- DOI
- 10.4168/aair.2020.12.2.292
- ISSN
- 2092-7355
- Abstract
- Purpose: While there is an urgent need for diagnosis and therapeutic intervention in patients with primary immunodeficiency diseases (PIDs), current genetic tests have drawbacks. We retrospectively reviewed the usefulness of flow cytometry (FCM) as a quick tool for immunophenotyping and functional assays in patients suspected to have PIDs at a single tertiary care institute. Methods: Between January 2001 and June 2018, patients suspected of having PIDs were subjected to FCM tests, including lymphocyte subset analysis, detection of surface- or intracellular-target proteins, and functional analysis of immune cells, at Samsung Medical Center, Seoul, Korea. The genetic diagnosis was performed using Sanger or diagnostic exome sequencing. Results: Of 60 patients diagnosed with definite or probable PID according to the European Society of Immune Deficiencies criteria, 24 patients were provided with useful information about immunological dysfunction after initial FCM testing. In 10 patients, the PID diagnosis was based on abnormal findings in FCM testing without genetic tests. The FCM findings provided strong evidence for the diagnosis of severe combined immunodeficiency (n = 6), X-linked chronic granulomatous diseases (CGD) (n = 6), leukocyte adhesion deficiency type 1 (n = 3), X-linked agammaglobulinemia (n = 11), autoimmune lymphoproliferative syndromeFASLG (n =1), and familial hemophagocytic lymphohistiocytosis type 2 (n = 1), and probable evidence for autosomal recessive-CGD (n = 2), autosomal dominant-hyper-immunoglobulin E (IgE)-syndrome (n = 1), and STAT1 gain-of-function mutation (n = 1). In PIDs derived from PIK3CD (n = 2), LIZBA (n = 2), and CTI,A4 mutations (n = 3), the FCM test provided useful evidence of immune abnormalities and a tool for treatment monitoring. Conclusions: The initial application of FCM, particularly with known protein targets on immune cells, would facilitate the timely diagnosis of PIDs and thus would support clinical decisions and improve the clinical outcome.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/26084)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.